Skip to main content
Funded Studies

Emmanouil Metzakopian, PhD

UK DRI Fellow at UK Dementia Research Institute at the University of Cambridge

Location: Cambridge United Kingdom

Emmanouil Metzakopian, PhD, is a UK DRI Research Group Leader and Fellow at the University of Cambridge and a principal investigator funded by Parkinson’s Disease UK and Open Targets. Since 2013 he has been developing CRISPR-Cas9 genetic screening tools and working on genome-scale genetic screens to identify genes that confer resistance to oxidative and ER stress in dopamine neurons. He was recently involved in producing the first genome-wide guide RNA-arrayed screening libraries for CRISPR-Cas9, which are being distributed by MERCK-SIGMA. The aim of the projects in his lab is to identify novel drug targets and biomarkers for neurodegenerative diseases. Dr. Metzakopian received his PhD from University College London and the National Institute for Medical Resrearch (now part of the Crick Institute), where he worked on understanding midbrain dopamine neuron specification and differentiation.

Associated Grants

  • Measuring Lipids in iPSC-derived Dopamine Neurons to Identify Parkinson’s Biomarkers


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.